特发性肺间质纤维化急性加重治疗新进展  

Research progress on treatment of acute exacerbation of idiopathic pulmonary fibrosis

作　　者：杜昀泽[1] 赵辉[1] 

机构地区：[1]天津市人民医院呼吸科,300121

出　　处：《国际呼吸杂志》2016年第15期1192-1196,共5页International Journal of Respiration

摘　　要：特发性肺间质纤维化急性加重造成病情急剧恶化，病死率高达85％，目前治疗尚未形成共识。认为有助于改善患者预后的治疗措施包括：免疫抑制剂联合糖皮质激素、多黏菌素一昏聚苯乙烯纤维柱血液净化去除选择性免疫系统细胞及介质、降钙素原指导抗生素使用、抑酸治疗及无创机械通气。Acute exacerbation of idiopathic pulmonary fibrosis results in sudden progression of the disease, mortality rate was 85%. But up till now, the treatment regiments have yet not reached a consensus. Nevertheless, treatment regiments for AE-IPF associated with a better prognosis include： combined use of corticosteroids and immunosuppression, removal of selective immune system cells and mediators with hemoperfusion through polymyxin B-immobilized fiber column, procalcitonin-guided antibiotic use, anti-acid therapy, and noninvasive ventilation.

关 键 词：特发性肺间质纤维化急性加重 药物治疗 临床试验 

分 类 号：R563.9[医药卫生—呼吸系统]